Axovant Sciences Ltd. (AXON) Given a $32.00 Price Target by Piper Jaffray Cos. Analysts
Axovant Sciences Ltd. (NYSE:AXON) has been assigned a $32.00 target price by analysts at Piper Jaffray Cos. in a report issued on Friday. The brokerage currently has a a “buy” rating on the stock. Piper Jaffray Cos.’s target price would suggest a potential upside of 111.36% from the stock’s current price.
Several other equities analysts have also recently commented on the stock. Leerink Swann reissued a “buy” rating on shares of Axovant Sciences in a research report on Thursday, June 30th. Zacks Investment Research cut shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. JMP Securities reissued an “outperform” rating and set a $36.00 target price on shares of Axovant Sciences in a research report on Tuesday, August 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Axovant Sciences in a research report on Tuesday, June 7th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $24.02.
Shares of Axovant Sciences (NYSE:AXON) traded down 1.59% during midday trading on Friday, reaching $14.90. The company had a trading volume of 645,142 shares. The firm’s market capitalization is $1.48 billion. Axovant Sciences has a one year low of $8.86 and a one year high of $21.30. The company has a 50 day moving average price of $15.99 and a 200-day moving average price of $13.42.
Axovant Sciences (NYSE:AXON) last posted its earnings results on Monday, August 15th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. On average, analysts anticipate that Axovant Sciences will post ($1.68) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Capital Management LLC raised its position in Axovant Sciences by 0.6% in the second quarter. Janus Capital Management LLC now owns 4,649,151 shares of the company’s stock worth $59,694,000 after buying an additional 28,512 shares in the last quarter. Franklin Resources Inc. raised its position in Axovant Sciences by 5.9% in the second quarter. Franklin Resources Inc. now owns 1,270,682 shares of the company’s stock worth $16,316,000 after buying an additional 70,900 shares in the last quarter. Ghost Tree Capital LLC acquired a new position in Axovant Sciences during the second quarter worth $7,383,000. BlackRock Fund Advisors raised its position in Axovant Sciences by 69.2% in the second quarter. BlackRock Fund Advisors now owns 574,250 shares of the company’s stock worth $7,373,000 after buying an additional 234,904 shares in the last quarter. Finally, Citadel Advisors LLC raised its position in Axovant Sciences by 850.3% in the second quarter. Citadel Advisors LLC now owns 572,679 shares of the company’s stock worth $7,353,000 after buying an additional 512,413 shares in the last quarter. Institutional investors and hedge funds own 29.45% of the company’s stock.
About Axovant Sciences
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.